SEC Filings

S-1/A
AVEXIS, INC. filed this Form S-1/A on 02/01/2016
Entire Document
 

Table of Contents

 


The Offering

Common stock offered by us

  4,250,000 shares

Common stock to be outstanding after this offering

 

21,900,603 shares

Option to purchase additional shares

 

The underwriters have a 30-day option to purchase a maximum of 637,500 additional shares of common stock.

Use of proceeds

 

We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be $76.5 million, or $88.4 million if the underwriters exercise in full their option to purchase additional shares, assuming the shares are offered at $20.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus.

 

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our ongoing Phase 1 clinical trial and future SMA trials for AVXS-101, manufacturing activities to support our ongoing and future trials for AVXS-101, including the establishment of our own manufacturing facility, and for general corporate purposes and working capital. See "Use of Proceeds" on page 75.

Risk factors

 

See "Risk Factors" beginning on page 11 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock.

Directed Share Program

 

At our request, the underwriters have reserved for sale at the initial public offering price up to 212,500 shares of our common stock, or 5.0% of the shares offered by this prospectus, for our employees, directors and other persons associated with us. Any shares of common stock sold to our directors, executive officers or employees pursuant to the directed share program are subject to the 180-day lock-up restriction described in the "Underwriting" section of this prospectus with respect to the directed shares sold to them. The number of shares of our common stock available for sale to the general public in this offering will be reduced by the number of shares sold pursuant to the directed share program. Any directed shares not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. The directed share program will be arranged through Jefferies LLC.

Proposed NASDAQ Global Market symbol

 

"AVXS"



          The number of shares of our common stock to be outstanding after this offering is based on 17,650,603 shares of our common stock (including preferred stock on an as-converted basis) outstanding as of September 30, 2015 and includes 1,750,794 shares of common stock issued

7



© AveXis, Inc. All Rights Reserved.